8 videos that explain the tension between HIV activists and Big Pharma
From Hollywood blockbusters, to investigative documentaries, to our own short, satirical animation, here are eight videos that show how the...
Patent on Hep C drug rejected in Ukraine: Price of sofosbuvir will significantly reduce
The Ministry of Economic Development and Trade of Ukraine (MEDT) refused to grant the pharmaceutical company Gilead a patent for...
Patent law amendments approved by the Government of Ukraine
Stricter patent law amendments, proposed by our partner, the All-Ukrainian Network of People Living with HIV/AIDS (the Network), have been...
Fundación GEP opposes patent on HIV drug Tenofovir (TAF) in Argentina
Pharmaceutical patent would block access to HIV medicines. Our partner is opposing the patent application in a bid to make...
Fixing the broken patent system: From Marrakech and back again
Marrakech was home to the signing of the TRIPS Agreement in 1995, an agreement that has been exploited by pharmaceutical...
Storify: Pathways to Access #GSIPA2M
[View the story “Pathways to Access! #GSIPA2M (15-17 Jan 2018)” on Storify] SaveSave
GSIPA2M: The Summit Highlights
Catch up on the activity from our inaugural Global Summit on Intellectual Property and Access to Medicines (15-17 January 2018)....
GSIPA2M: Malaysia Ministry of Health 2018 winner of the Leadership Award on Intellectual Property and Access to Medicines
Malaysia’s “historic decision” to issue a compulsory license on Hep C medicine, sofosbuvir, stands up to Big Pharma, and will mean...
IP and access to medicines: welcome speech
Our inaugural Global Summit on Intellectual Property and Access to Medicines has started today. Read Solange Baptiste’s welcoming speech below,...
Pathways to Access: Our global summit on intellectual property and access to medicines
23 years after the Trade Related Aspects of Intellectual Property Rights (TRIPS) Agreement was signed in Morocco, our inaugural conference...